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Abstract
Introduction: Two approaches were compared for the calculation of coefficient of variation (CV) and bias, and their effect on sigma calculation, 
when different allowable total error (TEa) values were used to determine the optimal method for Six Sigma quality management in the clinical la-
boratory.
Materials and methods: Sigma metrics for routine clinical chemistry tests using three systems (Beckman AU5800, Roche C8000, Siemens Dimen-
sion) were determined in June 2017 in the laboratory of Peking Union Medical College Hospital. Imprecision (CV%) and bias (bias%) were calculated 
for ten routine clinical chemistry tests using a proficiency testing (PT)- or an internal quality control (IQC)-based approach. Allowable total error from 
the Clinical Laboratory Improvement Amendments of 1988 and the Chinese Ministry of Health Clinical Laboratory Center Industry Standard (WS/
T403-2012) were used with the formula: Sigma = (TEa − bias) / CV to calculate the Sigma metrics (σCLIA, σWS/T) for each assay for comparative analysis. 
Results: For the PT-based approach, eight assays on the Beckman AU5800 system, seven assays on the Roche C8000 system and six assays on the 
Siemens Dimension system showed σCLIA > 3. For the IQC-based approach, ten, nine and seven assays, respectively, showed σCLIA > 3. Some differ-
ences in σ were therefore observed between the two calculation methods and the different TEa values. 
Conclusions: Both methods of calculating σ can be used for Six Sigma quality management. In practice, laboratories should evaluate Sigma multi-
ple times when optimizing a quality control schedule.
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Introduction
Clinical laboratory testing results are important for 
ensuring patient safety. Approximately two-thirds 
of important clinical decisions on patient manage-
ment are based on laboratory test results (1). 
Therefore, continuous improvement and the mini-
mizing of errors in testing are the major goals of 
every clinical laboratory. Six Sigma (6σ) quality 
management is a data-based, customer-centered, 
advanced quality management model that has 
been recently developed and is used globally. Fol-
lowing its introduction in clinical laboratories, 6σ 
quality management has become a major research 
focus (2). Sigma (σ) metrics evaluate process capa-
bility. The clinical application of 6σ quality man-
agement involves the combined use of quality re-
quirements and laboratory performance to quan-
titatively evaluate whether a laboratory meets 
clinical testing standards. This evaluation is typi-
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cally based on the expected defect rate. The ulti-
mate goal of 6σ quality management is to imple-
ment laboratory risk management and thus en-
sure patient safety.
Several studies on the application of 6σ manage-
ment in laboratory testing have been reported, in-
cluding studies on theoretical methods and their 
significance, the evaluation of performance of dif-
ferent assays, and the optimization of quality con-
trol (QC) schedules based on performance evalua-
tion (3-5). Sigma metrics quantitatively estimates 
quality based on the traditional parameters used 
in the clinical laboratory: allowable total error 
(TEa), bias and imprecision. Imprecision is usually 
expressed as standard deviation (SD) or coefficient 
of variation (CV). However, the quality require-
ments of various sources may be associated with 
differences within the same assay, which can af-
fect the parameter selection. Furthermore, differ-
ent approaches to bias and CV calculation may in-
fluence the final σ calculation. Laboratories should 
thus be aware of such sources of variation when σ 
management is applied, as they may modulate the 
value of σ and the accuracy of σ measurement. For 
example, previous studies have reported bias in 
external quality assessment (EQA) survey reports 
(e.g., College of American Pathologists or the Ran-
dox International Quality Assessment Scheme), 
whereas CV is derived from the cumulative coeffi-
cient of variation of internal quality control (IQC) 
materials (6-9). However, a strong correlation has 
been established between CV and the concentra-
tion of the test substance. If the concentration of 
IQC materials differs significantly from that of pro-
ficiency testing (PT) samples used in bias calcula-
tion, this method is inadequate for calculating σ. 
Bias may also be derived from reagent package in-
serts (10). Given that the cumulative average value 
of QC material may change over time, it is inappro-
priate to use the target value from manufacturers’ 
QC material when calculating bias. In fact, with the 
continuous development of information technol-
ogy, vendors can statistically analyse IQC data 
from the majority of laboratories to determine a 
more appropriate “group mean”. This approach 
can facilitate inter-laboratory quality management 
based on IQC, which has become popular among 
clinical laboratories. Using this group mean to cal-
culate for bias has been shown to be a convenient 
and reliable method.
Therefore, in the present study, we aimed to com-
pare two approaches to the calculation of CV and 
bias and the effect on σ calculation at different 
TEa. The two methods used to calculate the σ val-
ue for 10 routine biochemical assays on three dif-
ferent analysers were a PT-based approach, where 
materials for routine clinical chemistry from the 
China National Center for Clinical Laboratories 
(NCCL) were evaluated for imprecision (CV%) in 
each assay and bias (bias%) was calculated by 
comparison with the group mean for each PT sam-
ple in the NCCL report; and an IQC-based ap-
proach, where IQC results were used to calculate 
the CV% of each assay and bias% was calculated 
by comparison with the global group mean. Both 
methods thus harmonized the source of bias and 
CV derived from the same sample, based on which 
variations in σ were compared despite the differ-
ent sources of parameters. This method of evaluat-
ing σ has not previously been reported.
Materials and methods
Materials
Ten assays were evaluated using the manufactur-
er/analyser combinations routinely used in Peking 
Union Medical College Hospital (Table 1). All rea-
gents and calibrators for the three analysers were 
obtained from the original manufacturer except 
for creatinine (CREA; Maccura Biotechnology Co., 
Ltd., Chengdu, China) and bilirubin, total (BT; Wako 
Pure Chemical Industries, Ltd., Osaka, Japan) on 
the Beckman AU5800 system (Beckman Coulter, 
Inc., Brea, USA).
Methods
Sample preparation. PT materials (five lots: 201721–
201725) for routine clinical chemistry were provid-
ed by NCCL (Peking, China). Samples were pre-
pared using an analytical balance with an accuracy 
of 0.001 g. Powdered samples were dissolved in 3 
mL deionized water, capped, maintained at room 
temperature for 30 min and gently mixed until 
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completely dissolved. Samples were protected 
from light and stored between 2 °C and 8 °C until 
use within 7 days.
Imprecision evaluation. During the PT period (June 
5 – 9, 2017), the Clinical Laboratory Standards Insti-
tute (CLSI) EP15A3 protocol was followed, with the 
same sample tested five times daily for albumin 
(Alb), alanine aminotransferase (ALT), potassium 
(K), sodium (Na), chloride (Cl), calcium (Ca), total 
bilirubin (BT), glucose (Glc), creatinine (CREA, enzy-
matic), and urea (Urea) on each analyser for five 
consecutive days (11). The mean, SD (within labora-
tory) and CV (within laboratory) for each test item 
was calculated.
Bias calculation. Based on NCCL routine clinical 
chemistry requirements, the mean value of the in-
strument group (excluding data more than two 
standard deviations away from the mean) was 
used to verify the target value of each assay. Our 
mean (N = 25) for each assay from the different an-
alysers was calculated as described above. Bias% 
was determined as (our mean − mean of all labora-
tories using the same instrument and method) / 
(mean of all laboratories using the same instru-
ment and method) x 100.
Bio-Rad (Bio-Rad Laboratories, Inc., Hercules, CA, 
US) Liquid assay multiqual QC materials (694/696; 
lot numbers 45751, 45753) were used daily to mon-
itor internal testing quality. All assays participated 
in the Bio-Rad global report. Data were collected 
from internal QC at Peking Union Medical College 
Hospital from January 1, 2017 to June 30, 2017. 
Monthly (June 2017) mean, SD and CV were calcu-
lated. Bias was calculated based on target value, 
which was averaged from the Bio-Rad global re-
port for the same assay performed with the same 
instrument/method.
Sigma calculation and data analysis. According to 
quality requirements, the formulas σ = (TEa − 
|Bias%|) / CV (for percentage) and σ = (TEa − |Bias|) 
/ SD (for concentration value) were used to calcu-
late σ metrics for each assay. The allowable total 
error of each assay was based on the American 
Clinical Laboratory Improvement Amendments of 
1988 (CLIA ‘88) and People’s Republic of China 
Health Industry Standard (WS/T403-2012), desig-
nated as TEaCLIA and TEaWS/T, respectively (12,13). 
The specific requirements of the 10 assays are list-
ed in Table 2. Excel 2010 software (Microsoft Cor-
poration, Redmond, Washington State, US) was 
used for data analysis and graphing.
Results
PT Sigma metrics 
The σ values calculated using two TEa sources 
(σWS/T and σCLIA) for the three analysers are shown 
in Table 3. The TEaCLIA used absolute bias in the K, 
Na and Ca assays, whereas TEaWS/T used percent-
age bias in all other assays and was more stringent 
than TEaCLIA. We showed that σWS/T < σCLIA for all 
Analyser
Number of laboratories in NCCL proficiency testing/Bio-Rad global report
Alb ALT BT Glc CREA Urea K Na Cl Ca
Beckman 
AU5800*
207/37 221/148 220/60§ 208/48 138/22║ 210/22 371/46 359/46 364/44 202/39
Roche 
C8000†
419/26 410/16 369/26 392/32 384/22 399/22 401/36 388/36 387/35 395/25
Siemens 
Dimension‡
7/60 6/16 6/24 8/68 7/37 8/43 8/57 8/56 8/54 7/62
*Beckman, Beckman Coulter, Inc., Brea, CA. †Roche, Hoffmann-La Roche Ltd., Basel, Switzerland. ‡Siemens, Siemens Healthcare 
Diagnostics, Inc., DE, US. §Wako, Wako Pure Chemical Industries, Ltd., Osaka, Japan. ║Maccura, Maccura Biotechnology Co., Ltd., 
Chengdu, China. Alb - albumin. ALT - alanine aminotransferase. BT - bilirubin, total. Glc - glucose. CREA - creatinine. K - potassium. 
Na - sodium. Cl - chlorides. Ca - calcium. NCCL - China National Center for Clinical Laboratories, Peking, China.
Table 1. Reagents, equipment and number of laboratories included in each instrument group for NCCL proficiency testing, and num-
ber of laboratories included in the Bio-Rad global report for the same instrument/method
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assays except Na. For σWS/T, only the Siemens Di-
mension analyser achieved 6σ for BT testing in all 
five lots. The 3σ level was achieved for ALT, CREA 
and K on all three analysers; BT, Glc and Na on the 
Roche C8000 analyser; and Cl and Ca on the Beck-
man AU5800 analyser.
The σCLIA calculation based on TEaCLIA showed that 
eight assays (all except Urea and Na) achieved σ > 
3 on the Beckman AU5800 analyser. Among the 
eight, CREA and K reached 6σ levels in the five lot 
numbers during proficiency testing; four assays 
(ALT, BT, Cl and Ca) achieved 5σ. For the Roche 
C8000 analyser, all assays except Urea, Na and Cl 
achieved 3σ, whereas BT, Glc, CREA and K reached 
6σ. For the Siemens Dimension analyser, BT and K 
reached 6σ; ALT, CREA and Urea reached 4σ; and 
Alb, Glc, Na (201721, 201724, 201725) and Cl 
(201721) were < 3σ at certain concentrations.
Significant differences in σCLIA values were ob-
served using the same assay at the same concen-
tration but for different analysers. More intuitive 
σCLIA levels for all assays at different concentrations 
Table 2. Allowable total error derived from the US Clinical Labo-
ratory Improvement Amendments 1988 (CLIA ‘88) and the Peo-
ple’s Republic of China Health Industry Standard (WS/T403-2012) 
Item TEaCLIA TEaWS/T
bias% (absolute value) bias%
Alb 10 6
ALT 20 16
BT 20 (6.84) 15
Glc 10 (0.33) 7
CREA 15 (26.5) 12





TEaCLIA - allowable total error derived from US Clinical 
Laboratory Improvement Amendments 1988 (CLIA ‘88). 
TEaWS/T - allowable total error derived from the People’s 
Republic of China Health Industry Standard (WS/T403-2012). 
Alb - albumin, g/L. ALT - alanine aminotransferase, U/L 37 °C. 
BT - bilirubin, total, µmol/L. Glc - glucose, mmol/L. CREA - 
creatinine, µmol/L. Urea, mmol/L. K - potassium, mmol/L. Na - 
sodium, mmol/L. Cl - chlorides, mmol/L. Ca - calcium, mmol/L.
Item Sample number




















































































































Alb 201721 46 49 51 1.0 1.4 0.8 - 1.2 - 1.0 5.8 8.4 6.6 5.2 4.6 3.7 0.3†
201722 24 26 26 1.2 3.0 0.8 - 2.2 0.5 2.6 6.4 3.2 9.5 3.1 1.9† 4.4
201723 32 35 35 1.0 2.1 1.3 - 1.8 - 0.4 3.6 8.5 4.5 4.8 4.4 2.6† 1.8†
201724 46 49 52 2.3 1.6 1.1 - 1.1 - 1.5 7.2 3.8 5.5 2.6† 2.1† 2.9† - 1.1†
201725 37 40 41 1.3 2.1 0.8 - 2.9 - 2.2 2.9 5.5 3.8 9.4 2.4† 1.9† 4.1
ALT 201721 160 153 164 0.6 1.0 0.9 - 2.8 - 2.3 - 1.3 27.7 18.3 21.5 21.3 14.2 16.9
201722 31 29 32 3.0 4.0 4.6 - 2.8 - 1.1 0.7 5.8 4.7 4.2 4.5 3.7 3.3
201723 77 74 81 0.8 2.7 2.4 - 3.4 - 3.3 0.1 19.8 6.2 8.2 15 4.7 6.6
201724 144 137 149 0.8 1.3 2.0 - 2.5 - 2.6 0.5 21.1 13.1 9.6 16.2 10.1 7.7
201725 100 97 105 1.2 1.7 1.8 - 4.7 - 3.4 - 2.6 13 10 9.7 9.6 7.6 7.5
BT 201721 128.1 121.1 129.4 1.1 0.8 0.7 - 6.3 - 4.0 - 6.8 13 19.6 18.6 8.3 13.5 11.5
201722 12.5 11.3 13.8 1.3 1.8 2.2 - 7.1 - 8.5 1.7 36.8* 27.6* 22.0* 6.3 3.6 6.1
201723 25.4 23.5 27.8 0.9 1.4 1.3 - 14.6 - 7.4 0.1 11.3 15 18.9 0.4† 5.5 11.7
201724 85.9 82.0 89.1 1.0 1.9 0.6 - 4.2 - 4.9 - 5.9 16 7.8 22.7 11 5.2 14.7
201725 38.16 35.9 41.0 1.3 1.2 1.3 - 12.9 - 7.8 - 4.0 5.6 10.4 12.3 1.7† 6.2 8.4
Table 3. Sigma metrics for the proficiency testing (PT)-based approach
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Item Sample number




















































































































Glc 201721 13.4 13.3 14.2 1.2 1.4 1.6 - 2.7 - 2.1 3.5 6.1 5.6 4.1 3.6 3.5 2.2†
201722 3.8 3.7 4.0 1.1 1.1 2.2 - 3.0 - 2.9 5.5 6.6 6.7 2† 3.8 3.9 0.7†
201723 6.6 6.6 7.1 1.4 1.1 2.4 - 3.1 - 2.8 4.5 5 6.9 2.3† 2.8† 4 1.1†
201724 10.8 10.8 11.5 1.3 1.2 1.8 - 2.8 - 2.6 4.3 5.4 6.2 3.2 3.2 3.7 1.5†
201725 7.3 7.2 7.8 1.4 0.9 1.4 - 4.5 - 4.5 2.4 3.8 6.5 5.3 1.7† 3 3.2
CREA 201721 466 464 452 0.8 1.2 0.7 - 0.2 2.1 0.4 19.4 11 21 15.5 8.4 16.7
201722 85 88 82 0.8 1.2 2.1 9.6 5.4 0.8 28.8* 20.2* 14.9* 3.1 5.3 5.3
201723 223 225 218 0.6 1.2 2.9 2.9 1.8 1.5 19.3 11.3 4.7 14.5 8.7 3.7
201724 469 467 455 0.8 1.1 1.2 - 0.7 1.4 - 0.7 17.4 12.2 11.9 13.7 9.5 9.4
201725 289 289 284 0.7 1.0 1.0 - 0.2 - 0.2 - 0.1 21.2 14.8 14.9 16.9 11.8 11.9
Urea 201721 17.41 17.58 18.17 2.0 3.6 1.3 - 3.9 - 2.6 0.2 2.6† 1.8† 7.1 2.1† 1.5† 6.3
201722 4.05 4.21 4.25 2.0 3.1 3.0 - 7.0 - 1.8 - 1.0 8.8* 7.1* 7.7* 0.5† 2† 2.4†
201723 9.31 9.49 9.77 2.2 3.0 1.4 - 5.1 - 2.4 - 0.4 2.5*† 2.6*† 6.9* 1.3† 1.8† 5.5
201724 15.39 15.62 16.12 1.7 3.6 1.8 - 4.0 - 2.5 - 0.6 3 1.8† 4.8 2.4† 1.5† 4.3
201725 11.11 11.28 11.76 2.4 3.3 1.9 - 6.1 - 4.2 - 0.9 1.2† 1.5† 4.2 0.8† 1.2† 3.7
K 201721 6.3 6.4 6.3 1.2 0.6 0.8 0.6 0.6 0.4 6.4* 12.8* 9.2* 4.7 9.6 6.9
201722 2.7 2.8 2.7 1.0 1.2 0.9 - 2.3 - 0.5 - 2.3 16.6* 14.7* 17.3* 3.8 4.7 4
201723 4.3 4.4 4.3 0.5 0.6 0.8 0.4 0.1 0.5 21.8* 20.0* 14.4* 10.9 10.5 7.2
201724 6.0 6.0 6.0 0.5 0.5 0.9 1.0 0.7 0.6 14.5* 17.0* 8.6* 9.8 12 5.9
201725 4.7 4.8 4.7 0.7 0.3 1.1 - 1.0 - 1.1 - 1.2 14.1* 31.1* 8.7* 7.3 16.4 4.4
Na 201721 157 159 155 0.8 0.6 0.7 0.1 0.4 - 1.4 3.2* 3.6* 1.8*† 5.1 6.1 3.9
201722 108 111 112 0.8 0.9 0.8 - 2.5 0.3 1.0 1.4*† 3.6* 3.3* 1.8† 4 3.9
201723 128 130 129 0.4 0.8 0.8 - 0.8 0.5 0.3 5.2* 3.4* 3.5* 7.1 4.5 4.6
201724 153 154 153 0.5 0.5 1.1 0.3 2.2 0.5 5.0* 0.9*† 2.0*† 8.1 3.8 3.3
201725 133 135 135 0.5 0.5 1.2 - 2.1 - 0.7 - 1.0 1.5† 5.1 1.7† 3.5 7.4 2.7†
Cl 201721 108 107 105 0.8 0.7 0.9 0.7 1.7 - 2.6 5.3 5 2.7† 4.1 3.5 1.6†
201722 76 72 72 0.6 0.8 1.2 0.9 3.9 - 1.4 7.2 1.4† 3 5.5 0.1† 2.1†
201723 89 86 85 0.4 0.6 0.9 0.7 2.9 - 2.0 10 3.7 3.3 7.7 2† 2.2†
201724 108 106 105 0.6 0.5 0.6 0.8 2.1 - 0.9 6.9 5.6 6.6 5.3 3.7 5
201725 96 94 93 0.5 0.4 0.7 - 1.1 1.4 - 2.8 7.7 9.7 3 5.7 7 1.6
Ca 201721 3.14 3.21 3.03 1.2 1.0 1.9 1.2 3.5 - 1.0 5.6* 4.4* 3.8* 3.1 1.5† 2.1†
201722 1.84 1.92 1.80 1.2 0.8 1.7 1.2 4.4 - 1.3 10.5* 10.9* 7.4* 3.3 0.8† 2.2†
201723 2.73 2.82 2.67 0.8 0.8 1.3 1.1 3.8 - 1.5 10.4* 6.5* 5.9* 5 1.5† 2.7†
201724 3.02 3.12 2.92 0.8 0.7 1.2 0.8 4.0 - 2.0 9.1* 6.0* 5.3* 5.1 1.4† 2.5†
201725 2.72 2.81 2.65 0.6 0.7 0.9 0.0 2.1 - 3.4 14.7* 9.9* 6.5* 8.8 4.2 1.7†
*TEa calculated by using absolute bias to calculate σ; not marked indicates using percentage bias to calculate σ. † Sigma values < 3. 
TEaCLIA - allowable total error derived from US Clinical Laboratory Improvement Amendments 1988 (CLIA ‘88). TEaWS/T - allowable 
total error derived from the People’s Republic of China Health Industry Standard (WS/T403-2012). Alb - albumin, g/L. ALT - alanine 
aminotransferase, U/L 37 °C. BT - bilirubin, total, µmol/L. Glc - glucose, mmol/L. CREA - creatinine, µmol/L. Urea, mmol/L. K - 
potassium, mmol/L. Na - sodium, mmol/L. Cl - chlorides, mmol/L. Ca - calcium, mmol/L.
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and with different analysers are shown in Supple-
mentary Figure 1. 
IQC Sigma metrics 
The σ metrics for the ten assays calculated from in-
ternal QC data (June 2017) are shown in Table 4. 
Similar to the PT results, σWS/T was < σCLIA in 9 out 
of 10 assays (all except Na), with ALT, BT and Glc 
reaching 6σ; Na reaching 4σ; and K and Ca reach-
ing 3σ on the Beckman AU5800 analyser. On the 
Roche C8000 analyser, Glc, CREA, K and Na reached 
the 6σ level; ALT, BT and Urea reached 4σ; and Ca 
reached 3σ. For the Siemens Dimension analyser, 
CREA reached 6σ, Alb reached 5σ, and Glc and K 
reached 3σ.
For σCLIA, all 10 assays were above 3σ on the Beck-
man AU5800 analyser, of which ALT, BT, CREA and 
Ca achieved 6σ at two levels of QC materials. For 
the Roche C8000 system, σCLIA < 1σ for Cl, whereas 
all other nine items were > 3σ, and BT, CREA, K and 
Ca achieved 6σ while ALT reached 5σ. For the Sie-
mens Dimension analyser, the σCLIA value for Glc, 
Na and Cl was < 3, but Alb, CREA, K and Ca 
achieved 6σ. Supplementary Figure 2 displays 
more intuitive σCLIA levels for the 10 assays at vari-
ous concentrations using the three analysers. We 
also calculated σ metrics for the 10 assays based 
on IQC data from January – June 2017 and ob-
served some differences compared with the σ 
metrics calculated from the IQC data in June (Sup-
plementary Table 1).
Comparison of σ Metrics Between Methods 
In Figure 1, the differences in σCLIA as calculated us-
ing the two methods and three analysers are 
shown. For some analytes, the values of σCLIA de-
rived from the two approaches are significantly 
different. For example, σCLIA for the PT-based ap-
proach versus the IQC-based approach at similar 
concentrations was 6.5 (201722) versus 3.9 (45751) 
for Alb and 1.4 (201722) versus 4.6 (45751) for Na on 
the Beckman AU5800 analyser. To allow compari-
son of the differences between the two methods 
of calculating σCLIA at similar concentrations, we 
have listed the σCLIA values from IQC materials and 
PT samples in Supplementary Figure 3.
Discussion
Evaluating the quality of laboratory testing is an 
important research topic in clinical laboratories. 
Six Sigma quality standards take bias (system er-
ror) and CV (random error) into account to system-
atically and extensively guide quality manage-
ment in clinical laboratories while analysing possi-
ble causes of error, identifying solutions, better as-
suring testing quality and optimizing the QC 
schedule. However, the optimum TEa, bias, CV, 
and other indicators to calculate 6σ remain un-
clear, particularly when the sources of bias and CV 
vary between laboratories. We therefore com-
pared two new approaches to calculate σ metrics 
as a future reference for the application of 6σ qual-
ity management in clinical laboratories. 
To our knowledge, the present study is the first to 
use PT samples to assess imprecision and further 
calculate σ values. We obtained CV values from 
these samples to ensure that the same source of 
bias and CV were used in σ calculations. Given that 
PT samples typically have five different levels of 
concentrations, and it is easier to cover different 
levels of an assay for medical decision-making, this 
approach conveniently evaluates σ at different 
concentrations to better indicate analyser perfor-
mance. A limitation of the PT-based approach is 
the assessment of short-term imprecision, which 
may lead to a lower CV and overestimated σ value. 
According to the manufacturer’s instructions for 
the PT materials, prepared samples are stable for 
only seven days, and so are unsuitable for use in 
long-term evaluations.
To compare differences in σ levels calculated by 
the two methods, we used the relatively long-term 
CV calculated in the same month of IQC data in 
the IQC-based approach, thus accounting for oth-
er factors (batch number, instrument status, cali-
bration, personnel, temperature, humidity, etc.). 
Our findings indicate that, for some assays, the σ 
values derived from the two approaches are sig-
nificantly different. These differences may clearly 
have significant outcomes for QC rule selection; 
for example, a 4σ method requires multi-rule QC 
while a 6σ method can be controlled by a simple, 
single-rule QC.
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Figure 1. Comparison of σCLIA values calculated using two methods for the same test item. Note: 201721–201725 represent the lot 
number of proficiency testing materials, and 45751 and 45752 represent the lot number of Bio-Rad chemistry quality control materi-
als. The horizontal lines indicate the 3σ level line. Alb - albumin, g/L. ALT - alanine aminotransferase, U/L 37 °C. BT - bilirubin, total, 
µmol/L. Glc - glucose, mmol/L. CREA - creatinine, µmol/L. Urea, mmol/L. K - potassium, mmol/L. Na - sodium, mmol/L. Cl - chlorides, 
mmol/L. Ca - calcium, mmol/L.
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Beckman AU5800 Roche Siemens Dimension
There may be several reasons for the difference 
between the two approaches. First, there may be 
obvious differences in analyte concentrations be-
tween the IQC control samples and the PT materi-
als. Second, the group mean might not have been 
appropriate. Third, systematic deviations may have 
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Item Control level




















































































































Alb L 24 26 24 2.0 2.7 1.0 - 2.7 - 1.1 - 0.2 3.7 3.3 9.8 1.7† 1.8† 5.8
H 39 42 40 1.9 1.4 1.0 - 2.3 - 2.3 0.6 4.1 5.5 9.4 2† 2.6† 5.4
ALT L 31 29 37 1.7 3.1 2.7 0.8 3.4 11.5 10.8 5.4 3.1 8.5 4.1 1.6†
H 184 173 200 0.9 1.1 1.4 0.7 1.5 8.2 17.2 16.9 8.6 12.8 13.2 5.7
BT L 10.1 8.8 11.0 1.6 2.5 2.8 1.5 - 4.4 13.0 41.8* 29.3* 18.0* 8.5 4.2 0.7†
H 115.4 108.2 116.6 1.3 0.9 0.7 0.6 - 2.6 - 1.2 15 19.3 26.9 11.1 13.7 19.7
Glc L 3.3 3.3 3.5 1.2 1.2 2.4 - 1.2 - 2.2 1.7 4.8 4 2.2† 7.3 6.5 3.5
H 20.3 20.1 20.8 1.1 1.1 1.2 - 0.5 - 1.9 0.8 5.9 4.6 5.1 8.6 7.4 7.6
CREA L 78 81 75 3.3 1.7 1.4 5.3 1.3 0.6 8.5* 18.1* 24.8* 1.8† 6.3 8.1
H 848 821 809 0.9 1.5 0.8 2.0 - 0.5 - 0.2 13.9 9.7 18.5 10.6 7.7 14.8
Urea L 5.05 4.9 5.24 3.1 1.7 2.7 - 4.8 0.1 - 0.3 4.7* 10.1* 7.1* 1† 4.7 2.9†
H 27.15 26.3 28.17 2.1 2.1 1.8 - 0.8 - 0.1 - 0.3 3.9 4.3 4.8 3.4 3.8 4.3
K L 2.6 2.6 2.4 1.2 0.8 1.0 0.7 - 0.8 - 2.2 16.1* 24.0* 18.6* 4.4 6.5 3.8
H 8.0 8.1 7.9 1.5 0.6 0.7 1.5 - 0.1 - 1.5 3.3* 10.8* 6.6* 3 9.9 6.5
Na L 115 115 115 0.8 0.6 0.8 0.0 - 0.4 - 1.7 4.6* 5.2* 2.1*† 5 6 2.9†
H 158 161 157 0.8 0.5 0.6 - 0.2 - 0.2 - 1.6 3.1* 4.4* 1.4*† 4.8 7.5 3.9
Cl L 78 76 75 0.8 0.7 0.8 0.9 4.4 - 3.2 5.1 0.9† 2.3† 3.8 -0.6† 1†
H 118 117 119 1.1 0.6 0.5 0.8 1.3 - 3.3 3.8 6.2 3.5 2.9† 4.5 1.5†
Ca L 1.48 1.51 1.4 1.6 1.2 1.9 0.1 0.7 - 3.2 10.4* 12.6* 7.5* 3.1 3.6 0.9†
H 3.28 3.35 3.22 0.9 0.9 1.1 0.9 1.6 0.6 7.1* 6.6* 6.8* 4.5 3.8 4.2
*Allowable total error (TEa) calculated by using absolute bias to calculate σ; not marked indicates using percentage bias to calculate 
σ. † Sigma values < 3. TEaCLIA - allowable total error derived from US Clinical Laboratory Improvement Amendments 1988 (CLIA ‘88). 
TEaWS/T - allowable total error derived from the People’s Republic of China Health Industry Standard (WS/T403-2012). Alb - albumin, 
g/L. ALT - alanine aminotransferase, U/L 37 °C. BT - bilirubin, total, µmol/L. Glc - glucose, mmol/L. CREA - creatinine, µmol/L. Urea, 
mmol/L. K - potassium, mmol/L. Na - sodium, mmol/L. Cl - chlorides, mmol/L. Ca - calcium, mmol/L.
Table 4. Sigma metrics for the IQC-based approach using one-month IQC data
been present, possibly due to the short detection 
time period when evaluating σ with PT. In addi-
tion, the σ value itself is influenced by both bias 
and imprecision, and in clinical laboratories, multi-
ple factors can influence these parameters. Where 
the σ value is not satisfactory, the cause should be 
determined, whether it is a bias or an imprecision 
issue, and an appropriate solution should be iden-
tified. In the PT-based approach, the imprecision 
was mostly acceptable, and the suboptimal 6σ val-
ues may have been mainly attributable to bias. If a 
laboratory wants to use individualized quality con-
trol rules, it may select one method for evaluating 
σ level and use another method for verification. 
We also compared the σ calculation in the IQC-
based approach during different time periods and 
found that the 1- and 6-month values differed sig-
nificantly for some analytes (Table 4 and Supple-
mentary Table 1). As greater imprecision is expect-
ed with prolonged time, 6-month σ values were 
expected to be lower. However, this was not ob-
served in all cases; for example, Glc (low QC level, 
45751) on the Siemens analyser was 2.5 at 1 month 
versus 5.1 at 6 months, and Urea (low QC level, 
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45751) on the Beckman analyser was 4.7 versus 7.2. 
From the original data analysis, the difference in 
Glc on the Siemens analyser was due to the larger 
CV observed in June. The difference in Urea on the 
Beckman analyser, however, may have been the 
result of periodic biases with different signs aver-
aged to an ignorable long-term bias. In practice, 
laboratories must take caution when implement-
ing “Westgard Sigma Rules” in quality control 
based on σ values, because these values may 
change continuously with respect to precision and 
bias arising, for example, from calibrations, rea-
gents, or personnel (4). As described previously, σ 
value between different periods for some analytes 
may differ, laboratory should monitor the σ level 
continuously when using individualized quality 
control rules based on the σ evaluation.
Bias can significantly impact the σ metric. It can 
(theoretically) be corrected, while imprecision is 
more difficult to influence. However, bias is gener-
ally more difficult to estimate. The most reliable 
way to do so is to use a reference method. Most 
studies, including the present study, use group 
means from EQA data on the same instruments 
and methods as a target, rather than the reference 
method. Therefore, the observed bias is only “arbi-
trary” instead of “true”. External quality assess-
ment peer group evaluation has also been shown 
to be insufficient in determining analytical quality 
and may compromise patient care, despite its ac-
ceptance by participating laboratories and manu-
facturers (14). This approach is therefore a limita-
tion of the present study, but also represents a 
common limitation of 6σ for quality management 
at present, as most routine laboratory testing does 
not have a reference method that can be conveni-
ently implemented. Determining bias from profi-
ciency testing or global QC reports thus remains 
the primary approach in current 6σ evaluations. It 
is therefore critical to select the appropriate group 
when using group mean to assess bias. In the PT-
based approach used in our study, group means 
were calculated after excluding data more than 
two standard deviations away from the mean in 
order to exclude extreme values. Compared with 
the IQC-based approach, the relatively small num-
ber of laboratories using Siemens instruments (< 
10) in the PT-based approach may have affected 
the reliability of the means. This limitation should 
be considered when selecting an appropriate 
method for σ calculation.
The TEa is another important parameter in σ cal-
culations, and extensive efforts to understand, es-
tablish and unify the quality of testing and analysis 
are ongoing. In May 2014, the European Federa-
tion of Clinical Chemistry and Laboratory Medi-
cine (EFLM) held its first meeting on countermeas-
ures in Milan, Italy, under the theme “Analytical 
performance targets set 15 years after the Stock-
holm Conference”. At the conference, experts 
made in-depth and detailed discussions on the 
progress and further understanding of setting up 
analytical performance goals in clinical laborato-
ries in the 15 years after the Stockholm meeting, 
and also issued a statement of synergies after the 
meeting (15). At present, TEa values are primarily 
derived from CLIA guidelines, although few re-
ports have used biological variations (6,7,9,16,17). 
In China, the Ministry of Health published analyti-
cal quality specifications for routine clinical bio-
chemistry (WS/T 403-2012) in 2012, derived from 
data on within-subject and between-subject bio-
logic variation, while taking into account the qual-
ity of analysis currently achievable. However, these 
standards are expert based and have the objective 
(at least for CLIA) to set broad quality limits that 
will include the majority of laboratories; CLIA 
guidelines, for example, are often considered 
“loose” in terms of analytical performance. The 
TEa value selection can lead to significant differ-
ences in the evaluation of σ values (10). This limita-
tion should be considered when selecting an ap-
propriate TEa for σ calculation.
We also compared the effects of TEa values on σ 
calculations. The σWS/T value was significantly low-
er than that of σCLIA in most assays, given that 
TEaWS/T is more stringent than TEaCLIA. For some 
assays, the analyser could not achieve even the 3σ 
level. In addition, absolute bias was used for the K, 
Na and Ca assays in the CLIA guidelines, and BT, 
Glc, Urea and CREA at the low levels, but all per-
centage bias was used for TEaWS/T. Therefore, for 
low-concentration specimens (201722, 45751), 
σCLIA was significantly higher than σWS/T for BT, 
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CREA, Urea, K and Ca. When screening TEa sourc-
es, the source most closely related to the perfor-
mance for a given laboratory should be selected 
to ensure continuous improvement in quality 
management. Laboratories should not pursue the 
best σ metrics as a laboratory goal, nor should 
they select the most stringent TEa sources, to 
avoid unnecessary burden on laboratories.
In the present study, only the reagents for CREA 
and BT on the Beckman AU5800 system were not 
obtained from the original manufacturer. The re-
sults showed a minimum σCLIA for BT and CREA of 
5.6 and 17.4, respectively, when calculated from 
proficiency testing samples, and 7.4 and 8.4, re-
spectively, when calculated from IQC. Both results 
were satisfactory. These findings indicate that 
both domestic and foreign reagents selected for 
routine laboratory testing can achieve a high qual-
ity level. 
The performance of the analysers was also com-
pared. The Beckman AU5800 and Roche C8000 
systems each reached 3σ levels for seven assays, 
while the Siemens Dimension analyser received 3σ 
levels for five assays. Different assays showed vari-
ations in performance among the analysers, al-
though these variations were not significantly dif-
ferent. A laboratory may select an analyser based 
on assay usage frequency while still considering 
the σ evaluation, thereby personalizing the selec-
tion. Different assays may be also assigned to dif-
ferent instruments based on these results. We 
found that, for the Siemens Dimension system, σ 
assessed by both methods had multiple values < 3 
(14% for PT samples, 20% for IQC materials). Given 
that the Siemens Dimension instrument in our lab-
oratory has been in daily use for more than 5 years, 
it was replaced by a new instrument in December 
2017.
In conclusion, both methods of evaluating σ in this 
study can be used to assess the performance of a 
specific analyser, despite the observed differences 
in σ calculated by different methods. In the practi-
cal application of σ metrics for QC management, σ 
should be evaluated multiple times when optimiz-
ing a QC schedule.
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